Global Rheumatoid Arthritis Diagnosis Test Market Is Expected to Be Valued at Us$ 738.7 Mn by the End of 2022
- Submitted by: justinbarnes123
- Views: 57
- Category: Other
- Date Submitted: 05/26/2016 10:48 PM
- Pages: 6
- Report this Essay
Global Rheumatoid Arthritis Diagnosis Tests Market: 2015 - 2022
Persistence Market Research
Global Rheumatoid Arthritis Diagnosis Test
market is expected to be valued at
US$ 738.7 Mn by the end of
2022 - Persistence Market Research
Persistence Market Research
1
Global Rheumatoid Arthritis Diagnosis Tests Market: 2015 - 2022
Persistence Market Research Released New Market Report “Global Rheumatoid Arthritis Diagnosis
Test market is expected to be valued at US$ 738.7 Mn by the end of 2022’.
The rheumatoid arthritis diagnosis tests market is expected to be valued at US$ 738.7 Mn by the end of
2022, expanding at a CAGR of 6.2% during the forecast period (2016–2022). Based on type of tests, the
rheumatoid arthritis diagnosis tests market is segmented into serology test and treatment monitoring
tests. Increasing incidence of autoimmune diseases, off-label prescription of NSAIDs and other pain
management drugs are projected to increase demand for RA diagnosis. In addition, extensive focus on
the high specificity and sensitivity of RA kits from kit manufacturers and favorable regulatory guidelines for
rapid RA diagnostic kits are expected to fuel market growth. Commercialization of rapid diagnostic test,
especially in anti-CCP test would provide key growth opportunities for RA test kits manufacturers.
However, higher costs of these test kits and limited sensitivity when performed as individual test are major
restraining factors for this market. Revenue contribution of anti-CCP test segment has been estimated to
be the highest, accounting for 31.0% of the total rheumatoid arthritis market share in 2015 and is
expected to be one of the most lucrative segments over the forecast period. Limited sensitivity of other
tests such as ANA antibody and RF test provide competitive advantage over anti-CCP test. However,
availability of these tests at remote location of Asia Pacific region is a major challenge for the market.
View Detail Report With TOC:...
Persistence Market Research
Global Rheumatoid Arthritis Diagnosis Test
market is expected to be valued at
US$ 738.7 Mn by the end of
2022 - Persistence Market Research
Persistence Market Research
1
Global Rheumatoid Arthritis Diagnosis Tests Market: 2015 - 2022
Persistence Market Research Released New Market Report “Global Rheumatoid Arthritis Diagnosis
Test market is expected to be valued at US$ 738.7 Mn by the end of 2022’.
The rheumatoid arthritis diagnosis tests market is expected to be valued at US$ 738.7 Mn by the end of
2022, expanding at a CAGR of 6.2% during the forecast period (2016–2022). Based on type of tests, the
rheumatoid arthritis diagnosis tests market is segmented into serology test and treatment monitoring
tests. Increasing incidence of autoimmune diseases, off-label prescription of NSAIDs and other pain
management drugs are projected to increase demand for RA diagnosis. In addition, extensive focus on
the high specificity and sensitivity of RA kits from kit manufacturers and favorable regulatory guidelines for
rapid RA diagnostic kits are expected to fuel market growth. Commercialization of rapid diagnostic test,
especially in anti-CCP test would provide key growth opportunities for RA test kits manufacturers.
However, higher costs of these test kits and limited sensitivity when performed as individual test are major
restraining factors for this market. Revenue contribution of anti-CCP test segment has been estimated to
be the highest, accounting for 31.0% of the total rheumatoid arthritis market share in 2015 and is
expected to be one of the most lucrative segments over the forecast period. Limited sensitivity of other
tests such as ANA antibody and RF test provide competitive advantage over anti-CCP test. However,
availability of these tests at remote location of Asia Pacific region is a major challenge for the market.
View Detail Report With TOC:...